Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

"Receiving approval for NorUDCA marks a transformational leap—not only for Shilpa Medicare but for millions silently suffering from liver disease. We are honored to be the first company globally to bring this innovative therapy to patients, reflecting our unwavering commitment to pioneering healthcare solutions and expanding access to life-changing treatments across India and beyond. We are excited to launch NorUDCA in India immediately and are actively pursuing approvals worldwide to ensure this vital therapy reaches patients everywhere in need."

India, 14/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Shilpa Medicare is committed to rapidly commercializing NorUDCA in India and pursuing international regulatory pathways, aiming to bring this life-altering treatment to patients on a global scale

Shilpa Medicare Limited is a fully integrated pharmaceutical group specializing in innovative Oncology and Non-Oncology APIs, Peptides, Polymers, New Biological Entities and differentiated finished dosage formulations such as Orally Dispersible Films and Transdermal Patches. The company offers end-to-end CDMO services to global pharmaceutical partners, supported by four advanced R&D centers and seven manufacturing facilities, consistently driving innovation and quality in healthcare. www.vbshilpa.com

Logo - https://mma.prnewswire.com/media/2489785/Shilpa_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/shilpa-medicares-norudca-makes-history-as-first-approved-nafld-therapy-worldwide-302528708.html